I am a Master of the arts but am involved in many types of investing and trading. My areas of research are primarily biotechnology and disruptive technology. I am interested in turnaround, contrarian, trend following, and (deep) value situations.I am developing proprietary, quantitative investment strategies; and I operate a website for investors and others.
Private investor seeks value with exponential growth potential. I share my opinions freely. Do your due diligence, seek professional advice if you feel you need it. I prefer to be long and highly concentrated as I take the time to pick winners.
Tony Schwartz, PhD is involved in several start-up biotechnology companies (Currently Founder/President of the Athencion Corp). In addition he works with the NIH/NCI to develop novel immunotherapies for cancer. He was formerly the president of the Interthyr Corp. which received FDA and CE mark approval of a medical device for thyroid disease and additionally had several small molecule drugs in preclinical development to the IND phase. He is the co-inventor and patent holder on several drugs that modulate the Toll-like Receptor signaling pathways and has published several publications in high impact factor peer-reviewed journals and books. His research and commercialization interests include cancer, autoimmunity and various endocrine diseases specifically focusing on CD47 and TLRs. Tony obtained his PhD in Biomedical Engineering as well as MBA curriculum at Colorado State University. His research focused the use of mesenchymal stem cells for bone regeneration after radiation therapy of osteosarcoma and Ewing’s sarcoma. His work also developed new radiation therapy protocols to increase tumor kill while protecting normal tissues. He also spearheaded an ongoing clinical trial for the treatment of toxic shock with one of the drugs he developed. In addition, he teaches/develops MBA courses at Johns Hopkins focusing on the finance industry in biotechnology. Tony obtained his BS and MS degrees in Electrical Engineering and Computer Science as well as Biomedical Engineering from The Ohio University.
China has become the #2 pharmaceutical market years ahead of projections and continues to be the fastest growing market in the world. China is $50 billion dollars a year into life science and healthcare development through over 160 government funding programs. VC investment, M&A transactions and cross-border partnering deals in China were all up significantly in 2012.
ChinaBio® Today focuses exclusively on the rapidly evolving life science industry in China, including biotech, pharma, medical device, diagnostics, services and tools. From our offices in Shanghai and San Diego, our industry analysts provide daily news, commentary and analysis on public and private China life science companies, as well as events and global issues affecting the China market.
Visit: ChinaBio Today (http://www.chinabiotoday.com)
ChinaBio LLC (http://www.chinabiollc.com)
My background is Engineering. I have both a BS and MS in Electrical Engineering. My specialties are in computer hardware and software. I have been an active investor for 10 years and now my full time activities are trading stocks. I swing trade using technical analysis.
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
I am an analyst and 2017 Level III Candidate in the CFA Program that has gained experience in the investment industry through positions as a proprietary trader and a portfolio management administrator. I began contributing to Seeking Alpha as a way to share my thoughts on the biopharmaceutical industry. I discussed ways to minimize risk in biopharmaceutical investing through conservative pipeline valuation and balance sheet analysis to identify companies presenting a compelling valuation to potential investors. I also touched on ways to apply knowledge of the markets to improve personal finance. My pieces included either stock-specific analysis or general biopharmaceutical investing discussion through my Biotech Weekly blog. My research appeared on the websites of CNBC, Seeking Alpha, Reuters, Google Finance, Morningstar, NASDAQ, and MarketWatch.
Note: Articles and comments are my own opinions, are not related to the opinions of my employer, and should not be considered investment advice. Make sure to do your own due diligence before making an investment decision. Thanks!
Jason Ditz is the News Editor for Antiwar.com. He has 10 years of experience in foreign policy research and his work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press.
Named by Fortune as one of its "50 Great Investors". Acknowledged as Cash Flow From Operations (CFFO) expert by WSJ, Fortune, Forbes.com and Smartmoney.com after developing a CFFO algorithm that predicts bankruptcies for seemingly healthy large NYSE and NASDAQ traded companies. Markowski also has CFFO algorithms that identify severely undervalued companies.
In September 2007 Equities Magazine column predicted the 2008 collapses for all five of the U.S. major brokers including Lehman, Bear Stearns and Merrill Lynch. Wholesale sell recommendations for the five based on macro-analysis of brokerage industry's negative cash flow due to "sub-prime mortgage revenue".
Founded: TrophyInvesting.com (2016), Dynastywealth.com (2014), Onlinefinancialsector.com (2007), StockDiagnostics.com (2002).
Currently: Analyst for Dynasty Wealth (focused on finding and covering disruptor companies that have 100X to 1,000X potential within 5 years).
Passion is recommending shorts for hyped companies that have inherently flawed negative CFFO models and ten baggers for those which are extremely undervalued based on their CFFO. Does not trade the markets and is instead a buy and holder.
Began career with Merrill Lynch in 1977 and was employed in early years by Oppenheimer and Donaldson Lufkin & Jenrette. Became CEO of a firm in 1990 that subsequently went out of business due to the firm’s having a net capital deficiency on January 15, 1991, the day before the first Gulf War broke out.
Markowski voluntarily left the broker industry in 1991. Most of his activities since have been in the financial information industry. The SEC and the NASD subsequently barred Markowski in 1995 from associating with a broker dealer. The bar related to activities that occurred in 1990, and before the war's breaking out which caused a severe lack of liquidity for the markets resulting in the firm's going out of business. Markowski appealed his bar to the U.S. Supreme Court which denied to hear his appeal. Markowski was not barred from being a registered investment advisor (RIA). However, Markowski chose not to pursuit a career as a RIA.
Full-time investor searching for talented operators, clean capital structures & scalable growth. No cigar butts or conventional wisdom. My investment philosophy is similar to how I live my life: acquire a few prized possessions at the right price, minimize clutter and maintain flexibility. Twitter: @indievestments
Steven Grey is the founder and managing principal of Grey Value Management, LLC, a privately-held investment entity.
Before founding Grey Value Management he was the Chief Investment Officer of Freedom Capital Partners, a firm based in Alexandria, Virginia managing in excess of $200 MM of private capital. Prior to Freedom Capital he helped launch and was Managing Director of Risk at Albright Capital Management, a Washington DC-based investment advisory firm chaired by Madeleine K. Albright, the 64th Secretary of State of the United States. At inception, Albright Capital managed over $300 MM across a wide spectrum of geographies and asset classes, with a focus on emerging markets. For several years he was co-manager of Windward Capital, LLC, an event-driven hedge fund that was launched in March 1999 and managed over $100 MM.
On occasion an activist investor, prior to his time with Windward Capital Steven ran Grey Value Holdings, LLC., an investment vehicle dedicated to leveraged buyouts which raised over $500 MM in capital. Before Grey Value Holdings he was an associate portfolio manager at Neuberger Berman Inc.
Steven was a teaching assistant at Columbia University’s Graduate School of Business, from which he graduated with an MBA in 1997. He also graduated from the Tulane University School of Law (JD) in 1995, studying law in both the US and Japan, with a focus on corporate and securities law. He received his BA from the University of Texas at Austin (honors) in 1990. He has testified as an expert witness in securities litigation, served as a panelist in investment conferences, and is registered under Series 7 and Series 63.
Steven began investing in stocks at the age of 13 with the purchase of a utility stock featuring a ridiculously high dividend. A Texan by birth, his global meanderings include over 3 years in Tokyo, as well as significant time spent in Hong Kong, Thailand, India, and various locations in Europe and elsewhere. Other sojourns include a wander through the alleyways of Byzantium in Istanbul, as well as multiple motorcycle journeys, including an 8,000 mile solo trip through the US, an excursion across Australia, and most recently a 6,000 mile loop through Canada.
His first real influence in investing was his father, a pilot by profession and still one of the shrewdest investors he has ever known. Steven's mentor in investment analysis was a legendary investor and fellow motorcyclist from Demopolis, Alabama who formerly co-managed (with a man later accused of breaking the Bank of England) one of the largest and most successful hedge funds of all time.
His interests include motorcycles, travel, art, literature, music, snowboarding, and flying. He is a member in good standing of the United States Coast Guard Auxiliary, Flotilla 51.
Jason Bond is an American stock trader, entrepreneur, and small cap expert. Jason teaches small cap swing trading at Jason Bond Picks. He is best known for his 2013 swing trading performance tripling the S&P 500 in the portfolio he manages. Jason’s small cap swing trading ideas are widely published on numerous financial sites and blogs. Prior to teaching small cap swing trading in 2011, Jason taught for the Webster Central School District in NYS from 2001 - 2011. Jason’s trading strategy attempts to capture gains in a stock within one to four days. He uses technical analysis to look for stocks with short-term price momentum. Jason is interested in the fundamental value of stocks but puts emphasis on price trends and patterns.
Darren owns ProActive Financial LLC where he provides Financial Planning and Analysis consulting services. Darren's education includes a Bachelors in Economics, an MBA, and a Certificate in Personal Financial Planning.
My Twitter Account: @SkinwalkerChart
I use several highly tuned algorithms to pick the hottest penny stocks. I'm looking for a minimal return of 100% from my stocks within a 1 day - 3 month period. Happy to discuss stocks or strategies.
Professionally licensed but commenting as an anonymous individual investor for informational and entertainment purposes only. Experienced in the industry since 1997 with an education in finance and economics. Prior to financial services industry, was a veteran of the armed services experienced in engineering and nuclear power operations.
Proud father of four. Living the American Corporate dream where you can have 7 layoffs in 10 years and survive all of them. Look to invest in good companies that say something about me. Learning to be more patient, learn from my past mistakes. Learn from others and listen to my conscience a little more when it tell me to buy or sell because it is usually right! I am here to help others make money and share in this wealth.
I am a highly trained professional equity analyst. My specialty is finding companies with excellent ratios of risk to reward. Before going independent, I was the head analyst at a boutique Israeli hedge fund. Today I am a consultant to several multibillion-dollar firms. I have covered many sectors, including technology, solar and semiconductors. I have learned to connect the dots and discern how forces in these various industries will affect individual companies. I am a big believer in analyzing investments from the top down. This means identifying themes and trends that can reveal where industries and individual companies will be in the future. There are no magic formulas for this process, just a lot of hard work. After I've found a company, analyzed it and concluded its value, then it is just like a poker game with endless cards. All we have to do is sit and wait for the next card to reveal itself and adjust our thesis accordingly. Once we find the true value of a company, we must ignore day-to-day market chaos. If we have done our research properly, we do not need to worry if the Dow goes up or down a particular day, week or month. Peter Lynch, Ben Graham and Phillip Fisher are my biggest influences. I encourage anyone who wishes to learn more about the market to read any of their books.
I am a private investor based out of Toronto, Canada and I have been investing since 2003. After 8 years in Corporate Finance with a Canadian Telecom company I have decided to dedicate myself full-time to the capital markets. I write on Seeking Alpha to demonstrate my financial analysis and writing skills across a variety of industries and to take advantage of any story-based trading opportunity that may arise. My passion and greatest depth of knowledge is on Canadian small cap stocks and I consider my blog posts to be some of my best work. I am interested in any freelance opportunities that may arise outside of Seeking Alpha on Canadian or American listed stocks.
I have a private small company with a few different revenue streams. I survive off of one particular stream and invest the other smaller streams into the market.
I consider myself a longterm value investor and am not risk averse. I have three seperate portfolios each holding one third of my capital.
My goal was to create a multiframed method of analysis that might allow the average retail investor to pick investments that have a high probability of doubling or tripling. I am willing to cut against the grain and take contrarian deep value bets based on price value inefficiencies. I would like to compound at 30% average yearly gains in an all of my accounts. I have had 2 years of compounding my money at over 300% in these accounts so I would be ahead of my current benchmarks. As of end of 2013.
However, I do not expect to be able to repeat my results over the long term by trading. In fact I expect to sometimes underperform the market as many of my ideas might take time to come to fruition. I will often use arbitrage opportunities or short term swings for smaller gains. I am working on fine tuning my methodology but I believe it is unique and should produce the minimum average of 30%. I am currently ahead in this race and can withstand a correction as my portfolio grows quickly. I am also willing to get defensive if need be to protect capital or even go 50%cash. I run this as a very concentrated portfolio.
One third of my capital goes in a DRIP that I average in monthly to seven companies. I change these companies yearly based on valuation and position size. I grow positions here over time and never want to hold more than 30 companies in this account.
One third goes into long term companies that I see huge growth potential.
One third is in speculative bio-tech, tech and just about anything else where I can understand the financial statement sheets on and has great possible momentum and catalysts.
I often find myself going against the current trends in the market as I see opportunity in others fear. That said I seem to invest in around 15 stocks at a time and try to focus investments into the company at the best value. I hope to earn a healthy return over the next ten years to twenty years.
I am also interested in working in the industry as a career change and am always open to advice. Anyone out there want a 36 year old intern with advanced degrees in other areas?
My main skills are finding deep value opportunities and lucrative swing trade opportunities. I seem to have found a lot of bottom entries even in today's markets. I am willing to learn, enjoy games/game theory, love to read and solve problems.
I am working on starting a limited partnership for 2015 or 2016 so that I can share my gifts with family and friends.
"What looks like a horrible disaster now could be an awesome opportunity." "Buy Cheap when the big funds and others are giving it away"
All the Best,
I am an active investor in IP-centric investments for 6 years. I specialize in high risk / high reward situations both public and private. It is important for investors to plan for all outcomes as the litigation surrounding the IP investment takes many twists and turns. Extracting profits and limiting exposure are the keys to success.
I hope to provide information and strategies, which both expert and novice IP investors can profit from.
Follow me on twitter for the latest updates in the IP space:
Dividends - Core:
DOW / CE / O / MO / OHI
Speculative - Growth:
GLUU / MATR / JAKK / RMTI
(as of 09/11/14)
Main goal; not waiting for retirement, live now with the benefits you earned and share it with loved ones.
Panoplos started his career as an embedded systems engineer, taking on various development and technical consulting roles at a world-renowned cellular handset manufacturer, contributing to projects that would prove to change the face of the wireless industry.
After achieving much success in the wireless space, Panoplos joined a US biometrics start-up and proved a key force of the company in developing the nascent market. Through these efforts, Panoplos helped grow the company to a global success and an eventual IPO.
With this experience under his belt, Panoplos made a transition from engineering to marketing and business development, and eventually founded a small consulting firm out of APAC with a vision to promote entrepreneurship in the region, jointly develop breakthrough technologies and incubate regionally based start-ups from concept to proven businesses with a global reach.
Panoplos is also an avid investor and active day trader with more than 10 years of experience trading in equities, options and futures, and has partaken in several successful private equity investments in a wide range of industries.
Participating in Seeking Alpha, Panaplos hopes to share with the community the many insights he has gained over the years of evaluating numerous companies and investment concepts with respectable levels of success.
I am individual investor with over 35 years investing experience. I have traded almost everything you can over that time. I prefer investing in microcaps as there can be above average rewards along with higher risk. The areas I follow very closely are: Technology, Intellectual Property, Precious Metals, Rare Earths, mining companies and Biotechs. Picking the emerging leaders can provide huge rewards for early investors. I blog on topics that are of interest to me and on ones that I hope will generate good discussion. I don’t consider myself an expert in any one area, but know a little about a lot of things. I believe as soon as we stop learning, we stop living.
I am also a guest contributor to the Patent Stock Review, the most comprehensive investment research and news aggregation service on Wall Street, covering publicly traded companies seeking to monetize their IP portfolios, or "Patent Play Stocks."
I’ve been interested in the market ever since the downturn in 2009. It wasn’t until this past year where I started to enhance my trading skills and invest. I am here to bounce ideas off other investors and interact with like-minded individuals looking to get ahead. My strategy is in finding small cap companies that are undiscovered by large investment firms, particularly businesses with solid fundamentals.
I am a long term trader, but occasionally play the shorts. Please feel free to message me or follow me on SA.
2013 portfolio finished up 160%
"It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price." -Warren Buffet
"Stock tips are tempting, but they’re not worth listening to. Tips are for waiters, not traders." -Jim Cramer
"If anyone ever tells you to pay for their investment advice, make sure you request last year's tax forms to prove it. "
"You must look at things in the aspect of eternity" - The Intelligent Investor
I am a retired wall street attorney. I started out specializing exclusively in securities law. As I developed my practice, it morphed into a corporate finance practice specializing in mergers and acquisitions, with the securities law aspects being secondary.
I'm not much for diversification. I tend to put a substantial amount in a few baskets and then watch those baskets very, very carefully.